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Abstract 
Here, we describe a plug-and-play microfluidic platform, suitable for protein crystallization. 
The droplet factory is designed to generate hundreds of droplets as small as a few nanoliters (2 to 
10nL) for screening and optimization of crystallization conditions. Commercially-available 
microfluidic junctions and tubing are combined to create the appropriate geometry. In addition, a 
“chemical library” is produced in tubing. The microfluidic geometry for a “crystallization agent-based 
chemical library” is validated by screening crystallization conditions of lysozyme. The microfluidic 
geometry for a “ligand-based chemical library” is also explored to co-crystallize the protein QR2 with 
a ligand, for the purposes of structure-based drug design. This platform mixes aqueous phases 
(containing the protein and the crystallization agent) and organic phases (containing the ligand), 
during the droplet generation and circulation without using any surfactant. The droplet composition 
is controlled by the respective flow-rates of the different solutions, and checked by measuring on-
line absorbance. The low volumes involved in the crystallization trials, the speed of execution and 
the absence of a microfabrication stage make our platform a cheap, easy-to-use and versatile tool 
for crystallization studies. 
1. Introduction 
Crystallization is used in many fields (biology, pharmacy, mineralogy, optics, for molecule 
separation and purification processes, and for control of product properties like size, shape and 
phase. Crystallization is also used for analytical purposes. For instance, protein crystallization is a key 
step in the determination of the three-dimensional structure of proteins by X-ray diffraction (XRD), 
allowing a better understanding of their biological functions. In addition, in pharmaceutical research, 
the co-crystallization of a target protein with many different ligands often enables the identification 
and design of new active pharmaceutical ingredients (APIs). This process is called structure-based 
drug design.1 However, obtaining large enough high-quality protein single crystals (about 100µm) 
remains a challenge in the determination of protein structures by XRD.2 
Crystallization is influenced by many parameters (pH, temperature, type of buffer and 
crystallization agent). Identifying the conditions to obtain suitable protein crystals is usually a two-
step process, based on a trial and error approach: first screening and then optimization of 
crystallization conditions. Moreover, nucleation being of a stochastic nature, it takes a large number 
of experiments to obtain reliable data.3, 4 However, proteins are generally expensive to produce and 
only available in small quantities. Consequently, it is expensive to identify protein crystallization 
conditions, both in terms of time and raw materials. The volumes involved in crystallization trials are 
therefore key to reducing experimental costs.  
A high-throughput approach to crystallization, and particularly to screening, is thus needed 
for industrial research and drug design. Two categories of tools have been developed for high-
throughput protein-crystallization trials. The first is high-throughput robots, like Mosquito® (TTP 
LabTech), Oryx8 (Douglas Instruments Ltd), or Phoenix (Art Robbins Instruments). They rely on 
automated liquid-handling integrated with dispensers and fluidic circuits, and are typically able to 
form droplets as small as 100nL.5 However, they are generally expensive.  
The second category of tool is based on microfluidic techniques, i.e. controlling and 
manipulating flows at low scales (micro, nano to picoliter) with miniaturized devices called lab-on-
chip.6 A very large number of microfluidic systems dedicated to the screening of crystallization 
conditions is available, based on different crystallization methods7 : free interface diffusion8, 9, 
counter diffusion10, 11, vapor diffusion12, 13, batch14, 15. Many crystallization experiments are carried 
out quickly, testing a lot of different crystallization agents at different concentrations. However, most 
of them are for single use and require complex external equipment (integrated valves and pumps, 
mixers, especially designed and microfabricated channels or chambers, multiple inlets of pressurized 
gas). Moreover, these devices may be expensive and/or difficult to use by non-specialists in 
microfluidics.  
We previously described a versatile, high-throughput droplet-based microfluidic platform for 
optimization of crystallization conditions.16 Hundreds to thousands of droplets as small as 2nL 
(hereafter nanodroplets) are generated in an oil flow, using only small quantities of materials. The 
use of surfactant is avoided because it is liable to disturb the nucleation process. Droplets are isolated 
from each other by oil, so that each droplet serve as an independent nano-crystallizer. This flexible 
platform combines material saving, speed of execution, ease of use and a large number of 
experiments for statistical validity. The parts of the set-up achieving droplet generation, mixing, 
detection and storage are all independent, commercially available modules and can be assembled 
according to the user’s needs (Figure 1):  
(1) The droplet factory: droplets are generated in Teflon tubing, using a syringe pump (Figure 
1a) and microfluidic junctions (Figure 1b) in which the dispersed phases (crystallization solutions) 
intersect an immiscible continuous phase. The dispersed phases mix as they form droplets, and the 
droplet composition is controlled by the solution flow-rates.  
(2) The on-line characterization module: each droplet can be characterized by its size, its 
frequency and its composition, by spectrophotometry (Figure 1c);  
(3) The droplet incubation module: this module involves a thermostatted tubing holder 
(Figure 1d) and an xyz-motorized camera for sequential acquisition (Figure 1e).  
 
Figure 1: Schematic illustration of the entire microfluidic platform16. (a) Syringe pump, (b) microfluidic 
junction, (c) on-line spectrophotometer, (d) thermostatted tubing holder, (e) xyz-motorized camera.  
Here, we describe the serial assembly of microfluidic junctions in the droplet factory without 
microfabrication. The aim is to increase the number of solution inlets and to adapt the geometry to 
protein crystallization. To perform screening, tubing is filled with solutions of different components, 
separated from each other by oil to prevent mixing. This tubing is a “chemical library”, containing 
different components involved in protein crystallization. These solutions are then added to 
nanodroplets of protein solution. Furthermore, we are able to mix two different phases (aqueous 
and organic) inside the droplets. Here, our microfluidic platform is applied to screening and 
optimization of crystallization conditions of lysozyme, and to quinone reductase 2 co-crystallization 
with ligand, for structure-based drug design purposes. 
1.1. Solutions 
All solutions were prepared using deionized pure water (Milli-Q® Direct, Merck Millipore). 
1.1.1. Lysozyme 
Hen-egg white lysozyme (14.6kDa) was purchased from Sigma (batch 057K7013 L 2879) and 
used without further purification. A suitable amount of lysozyme was solubilized in 80mM sodium 
acetate buffer at pH 4.5 (pH-meter pH210, HANNA Instruments). The lysozyme concentration of the 
solution was checked by measuring absorbance (Nanodrop® ND2000c) at 280nm 
(lysozyme = 2.64 mL.cm−1.mg−1) 17. The NaCl (4M), (NH4)2SO4 (4M) and KSCN (0.6M) solutions were 
prepared in acetate buffer.   
1.1.2. QR2 
Human quinone reductase 2 (QR2, also known as NQO2; EC 1.10.5.1) was produced in 
Escherichia coli (Protenia). Before use, flavin adenine dinucleotide (FAD) was added at a ratio of 
1.5mol of FAD for 1mol of QR2. The protein was then rinsed with its elution buffer (20mM Tris pH 8, 
150mM NaCl) and concentrated to 35mg.ml-1. QR2 concentration was checked by measuring 
absorbance at 450nm and 280nm (FAD450 = 11300L.mol-1.cm-1, FAD280 = 19900L.mol-1.cm-1, 
QR2280 = 44920L.mol-1.cm-1) (ExPASy, ProtParam18). The (NH4)2SO4 (3M) solution was prepared in the 
same elution buffer. QR2 crystallization conditions in our microfluidic set-up have previously been 
determined19: 20mM Tris–HCl, pH 8, 150mM NaCl, 5.5 mg.mL-1 QR2, 1.35M (NH4)2SO4 (Figure 2). 
 
Figure 2: Pictures of 3 representative droplets for QR2 crystallization in 3nL droplets. 20mM Tris–HCl, 
pH 8, 150mM NaCl, 5.5mg.mL-1 QR2, 1.35M (NH4)2SO4, 20°C.  
For QR2 co-crystallization experiments, we used a known ligand of this protein, melatonin20, 
solubilized in DMSO (Dimethyl sulfoxide) to 100mM. Then the ligand concentration in solution was 
adjusted to 6mM with 63% water. A surplus of ligand was added to the droplets, at a ratio of 10:1 
(nligand/nQR2).  
1.1.3. Dyes 
Colored solutions were prepared using food dyes in deionized water (5%, red dye Vahiné 
E122 and yellow dye Vahiné E102).  
1.2. Interfacial energy measurement  
Interfacial energies were measured by the hanging drop method21, using a contact angle 
measurement system OCA20 (Dataphysics) with the software SCA20.  
1.3. Microfluidic platform 
1.3.1. Materials 
The droplet factory was constructed from commercially-available polyetherether ketone 
(PEEK) junctions and Teflon-like tubing (IDEX Health and Science), initially designed for high-
performance liquid chromatography (HPLC) systems. These two materials were previously tested in 
our group and proved to be compatible with almost all solvents, showing excellent resistance and no 
solvent evaporation22.  
Droplet generation depends on flow-rates, viscosities, wettability of the tubing wall, 
interfacial energy between continuous and dispersed phases, tubing dimensions, and crossing angles 
of microfluidic tubing.23 Here, we used fluorinated ethylene propylene (FEP) tubing with inner 
diameter (ID) of 150µm and outer diameter (OD) of 1.59mm. Junctions all include an inlet for the 
continuous phase and an outlet for droplets, plus one or two other inlets to inject the dispersed 
phase(s), leading to two junction geometries. In a tee-junction (two inlets and one outlet), the 
dispersed phase and the continuous phase were injected via two perpendicular inlets.  In a cross-
junction, the continuous phase was injected via the inlet facing the outlet and two dispersed phases 
were injected face-to-face via the two other inlets. Hence the dispersed phases mix as they form 
droplets. Both tee- and cross-junctions are 150µm ID so as to generate from 2 to 10nL droplets. The 
flow-rates of the syringes containing the continuous and dispersed phases were precisely controlled 
(as low as 0.01μL/s) without pulses by a programmable pump system (neMESYS, cetoni GmbH). 
Continuous phase selection is essential for droplet stability. Two parameters are therefore 
decisive: viscosity, related to molecular weight (at constant chemical composition), and interfacial 
energy between the continuous phase and the dispersed phase, related to chemical composition. 
The less miscible the continuous phase is with the dispersed phase, i.e., the higher the interfacial 
energy, the more stable the droplets. Thus, fluorinated oils are typically chosen. We showed in a 
previous work how to choose conditions of droplet generation to obtain droplets that are 
homogeneous, in terms of size and frequency.24 Here, we used FC-70 oil (Hampton Research, 3M™ 
Fluorinert™) as continuous phase. This oil has no or very poor miscibility with both aqueous and 
organic solutions and good wettability with Teflon.22 
The characterization module consisted of a light source (from 215 to 2500nm, DT-MINI-2-GS, 
Ocean optics), a home-made tubing-holder (poly(methyl methacrylate)), two optical fibers (diameter 
400µm, premium-grade Patch Cords, QP400-1-UV-Vis, Ocean optics), a UV–Vis–NIR 
spectrophotometer (from 190 to 2300nm, USB2000+, Ocean optics) and software (OceanView, 
Ocean optics). 
The incubation and observation module comprised a thermostatted tubing holder 
(Anacrismat) and a camera (Alliance Vision) mounted on an xyz-motorized table with a motorized 
variable zoom.  
1.3.2. Set-up 
The cross-junction enables the mixing of two solutions in the droplets, for instance the 
protein solution and the crystallization agent solution. However, it may be necessary to add a ligand 
(for co-crystallization), or another crystallization agent (for screening), or an additive to the 
crystallization solution. Thus, several microfluidic junctions were mounted together to increase the 
number of inlets in the set-up. Here, the cross-junction was combined with a tee-junction, allowing 
a third solution to be injected into the droplets after their generation (Figure 3a). As the solutions 
injected into the cross and the tee junctions are miscible, the third solution can be added inside the 
pre-existing droplets.25 
Mixing was verified visually in a prior trial using yellow and red dyes in 500µm ID tubing (PFA-
Teflon, IDEX health and science), generating larger droplets (100nL). The yellow dye was injected 
into the cross-junction, while the red dye was injected into the tee-junction (Figure 3b). Droplet size, 
and thus homogeneity, was evaluated by length L (from pictures using the software ImageJ), and 
used to calculate the droplet volume.  
Depending on flow-rate, the red solution mixes well with the yellow droplets passing through 
the tee-junction, without creating a new interface and thus a new droplet. Moreover, at constant 
flows, the droplets at the outlet of the tee-junction are homogeneous both in terms of size and 
frequency. For a given size of yellow droplets generated in the cross-junction (i.e., for given flow-
rates in the cross-junction) (Figure 4a), increasing the flow-rate of the red solution resulted in an 
increased volume of red solution being added to the droplets (Figure 4b to k). Thus, the amount of 
solution added to the droplets was controlled by the flow-rate for the third solution, enabling the 
control of droplet composition.  
 
Figure 3: (a) Picture of droplet generation in a cross-junction combined with a tee-junction and (b) 
schematic representation of a trial with yellow and red dyes. 
 
Figure 4: (a) Droplets generated in the cross-junction. (b) to (k) Droplets obtained after adding red 
solution to yellow droplets through the tee-junction: from (b) to (k), the amount of red dye is 
increasing. Roughly 100 droplets are generated for each condition to check their that they are 
homogeneous in size and frequency.  
To test the feasibility of this procedure with lower volumes, the same experiment was realized 
in 150µm ID tubing (i.e. with 3nL droplets). As the droplets were roughly 30 times smaller, the 
amount of dyed solution added to droplets could not easily be checked visually. Therefore, we placed 
the on-line spectrophotometer (Figure 1c) after the tee-junction and we determined the red-dye 
concentration in the droplets by measuring the absorbance at 520nm. Figure 5 shows that the 
absorbance is proportional to the red-dye flow-rate, up to 30µL/h. above this threshold, the red-dye 
concentration falls beyond the linearity domain of Beer-Lambert’s law. In that case, we used image 
analysis to evaluate the concentration via the size of the droplets, which increases with the red-dye 
flow-rate: for a red-dye flow-rate of 0µL/h, droplet volume is 5nL, while for a red-dye flow-rate of 
80µL/h, droplet volume is 16nL. Hence the proportion of red dye in droplets increases from 0 to 
almost 70%, as shown by droplet color under equivalent conditions in 500µm tubing (Figure 4j). 
These experiments show that several microfluidic junctions can be combined to increase the 
number of inlets in the set-up. With appropriate flow-rates, the different solutions merge instead of 
creating new droplets in the tubing, and the amount of solution added to the tee-junction is 
proportional to the flow-rate. Droplet concentration can then be checked by on-line 
spectrophotometry. This set-up is applied to both protein-ligand co-crystallization and screening of 
crystallization conditions. 
 Figure 5: Droplet absorbance at 520nm as a function of the red-dye flow-rate in 150µm ID tubing.  
1.3.3. Chemical library 
The syringes used to inject the various fluids into the microfluidic system have a minimum 
filling volume of roughly 100µL. Since microfluidics consumes little material, droplets generation 
does not consume the entire volume in the syringe, which is wasteful. Our solution is not to fill the 
syringes, but to fill the tubing directly. To do so, the syringe and tubing of the selected length were 
first filled with oil (so as not to contaminate the solutions) and then the tubing was refilled with the 
solution of interest. This system was applied to screening by successively refilling the same tubing 
with plugs of different solutions (Figure 6). This tubing is the “chemical library” for the screening 
experiment. The solutions were separated from each other by an oil spacer to prevent them from 
mixing. Then the solutions were injected successively into the microfluidic system.14 For instance, a 
length of 15cm of 150µm ID tubing contains 2.7µL, corresponding to about 900 droplets of 3nL. 
Consequently, using plugs instead of syringes considerably reduces the consumption of materials, 
for instance by a factor 37 for 900 droplets. The length of the plugs, and thus their volume, depends 
on the number of droplets required by the user.  
 
Figure 6: Filling tubing with different solutions. (a) The tubing is first filled with oil (grey), and then 
refilled with the first solution (red). The tubing can be filled with different solutions, by interspacing 
oil between solutions. (b) Picture of tubing (FEP, 1.59mm OD, 150µm ID) containing first a red 
(0.22µL), then a yellow (0.13µL) and then a red dye (0.05µL), separated from each other by FC-70 oil. 
Arrows indicate the flow direction. 
2. Screening of crystallization conditions of lysozyme 
To apply our microfluidic platform to the screening of protein crystallization conditions, 
different solutions of crystallization agents have to be added successively to droplets. We performed 
a first experiment in 150µm ID tubing, using dyes instead of crystallization agents to make it easier 
to observe the droplets. Tubing containing dyes served as the “crystallization agent-based chemical 
library tubing”: we inserted a red plug, a yellow plug and another red plug (top of Figure 6), separated 
from each other by oil. Droplets were generated in a cross-junction, by injecting two flows of water 
face-to-face (instead of crystallization solution) and perpendicularly separated by FC-70 oil. The 
tubing at the cross-junction output was connected to a tee-junction. The dyes were added to droplets 
by connecting the tubing containing dyes to the tee-junction (Figure 7). At the tee-junction output, 
the droplets obtained were successively transparent (Figure 7a), red (Figure 7b), transparent (Figure 
7c), yellow (Figure 7d), transparent (Figure 7e) and red (Figure 7f). Thus, the different dyes and the 
oil contained in the tubing were injected successively into the droplets generated in the cross-
junction. There was no mixing between the different plugs. Droplets not containing dye, i.e. those 
that had passed through the tee-junction during oil injection, were very irregular in terms of size and 
frequency. The oil injection obviously destabilized the droplets, inducing their coalescence. 
conversely, the droplets to which dyes had been added were homogeneous (L400µm, i.e. 6nL). 
Thus, using “chemical library tubing” and a tee-junction, it is possible to add different aqueous 
solutions successively to aqueous droplets after their generation in a cross-junction.  
 
Figure 7: Successive addition of different solutions inside the droplets using the tee-junction and 
150µm ID tubing. (a) to (f) show droplets obtained from the addition of: (b-d-f) dyes and (a-c-e) oil. 
The flow-rates are: oil 130µL/h, water 60µL/h and dyes 20µL/h.  
The same set-up was used to add different crystallization agents to lysozyme droplets, to 
screen lysozyme crystallization conditions. Three crystallization agents were tested: (NH4)2SO4, NaCl 
and KSCN (top of Figure 8). Adding (NH4)2SO4 yielded no crystallization event (Figure 8a). Adding 
KSCN led to precipitates of lysozyme in the droplets (Figure 8b). Adding NaCl led to lysozyme crystals 
with two crystal habits (Figure 8c) that were previously observed26, 27: the first is the tetragonal stable 
phase and the second, with a sea-urchin-like habit, is a metastable phase.26 Here, applying our 
screening strategy to lysozyme led us to select NaCl as a crystallization agent. Thus, our microfluidic 
platform can be used to screen crystallization conditions of proteins by successively injecting 
different crystallization agents into protein droplets. 
 Figure 8: Screening of crystallization conditions of lysozyme. Three crystallization agents are injected 
into 10nL droplets. Crystallization conditions are lysozyme 33mg/mL in a buffer of sodium acetate 
80mM pH4.5, 20°C (a) (NH4)2SO4 1.1M, (b) KSCN 170mM, (c) NaCl 1.2M. Flow-rates are: oil 130µL/h, 
lysozyme 25µL/h, buffer 25µL/h, crystallization agents 20µL/h. These three sets of droplets are 
obtained in a single experiment. About 50 droplets are generated for each condition to check their 
regularity. 
Then, the crystallization conditions were optimized using the fine-gradient method16: NaCl 
and lysozyme solutions were injected into a cross-junction, varying the respective flow-rates to 
create a concentration gradient inside the droplets (top of Figure 9). In this way, a wide range of 
supersaturation was scanned. We obtained large single crystals of protein (Figure 9b). Thus, our 
microfluidic platform permits the screening and the optimization of crystallization conditions of 
proteins in droplets as small as 3.5nL, consuming little material (0.2mg of protein in total) and 
without using any surfactant. Moreover, the large number of identical droplets (at least 50 per 
condition) avoids the risk of false negative or positive results, and the final selection of crystallization 
condition is robust and reproducible.  
 
Figure 9: Optimization of crystallization conditions of lysozyme with the concentration gradient 
method in 3.5nL droplets. Crystallization conditions are sodium acetate 80mM pH 4.5, 15°C (a) 
Lysozyme 23mg/mL, 1.33M NaCl, (b) Lysozyme 35mg/mL, 1M NaCl, (c) Lysozyme 47mg/mL, 0.66M 
NaCl. These three sets of droplets are obtained in a single experiment. About 50 droplets are 
generated for each condition to check their regularity. 
3. Screening of ligands of QR2 by co-crystallization  
Our microfluidic platform can also be applied to the screening of ligands of proteins for 
structure-based drug design. To perform protein-ligand co-crystallization, the protein and the ligand 
have to be incubated together before surpersaturation is generated. Thus, protein and ligands were 
first mixed in the cross-junction, and second, the crystallization agent was introduced into the tee-
junction. The length of the tubing between the cross- and the tee-junctions was adapted to the 
ligand-protein binding affinity (the lower the binding affinity, the longer the tubing).  
A first experiment was performed in 150µm ID tubing, using dyes instead of ligands to make 
it easier to observe the droplets. Tubing containing dyes (the “ligand-based chemical library tubing”), 
and water (mimicking the protein solution) were used, as in part 2. Water and dyes were injected 
face-to-face into a cross-junction, generating dyed droplets in oil. Then water (mimicking the 
crystallization agent solution) was injected into droplets via a tee-junction (top of Figure 10). Mixing 
water with dyed droplets in the tee-junction led to colored droplets that were homogeneous both in 
terms of size and frequency (Figure 10b, d and f), as in the part 2.  
 
Figure 10: Successive addition of different solutions inside the droplets using the cross-junction in 
150µm ID tubing. (a) to (f) show the droplets obtained from adding: (b-d-f) dyes and (a-c-e) oil.  The 
flow-rates are: oil 140µL/h, cross-water 40µL/h, dyes 20µL/h and tee-water 30µL/h. 
However, ligands are usually only soluble in organic solvents whereas proteins are soluble in 
aqueous buffers. Thus, mixing ligand and protein solutions requires mixing two different phases 
during droplet generation. Note that the commonly used organic solvents are miscible with water 
(DMSO, ethanol). During droplet generation, we observed that droplets were at first regular (at the 
outlet of the cross-junction), but that they quickly coalesced in the tubing, especially since no 
surfactant was used to stabilize them. Indeed, the oil-water interfacial energy was higher than the 
oil-organic solvent interfacial energy (Table 1). 
Thus, mixing aqueous solution and organic solvent first creates an interfacial energy gradient 
with oil, between the organic solvent-rich areas and the water-rich areas (before homogenization). 
This variation of the interfacial energy probably leads to a Marangoni flow. The result is a disturbance 
in the movement of generated droplets, causing their coalescence, as previously shown in the case 
of the addition of a surfactant.28 Moreover, once the droplets are homogeneous, their interfacial 
energy with the tubing wall is much lower than for pure-aqueous droplets. Hence droplets tend to 
wet the tubing wall, also promoting their coalescence. Therefore, it is impossible to add a pure 
organic solvent to water without disturbing the flow of generated droplets. 
 
 
 
 
Table 1: Interfacial energy of various solvents with FC-70 oil (mJ.m-2) 
Solvent Interfacial energy  
Water 48.40 ± 0.51 
DMSO 18.14 ± 0.06 
DMF 14.46 ± 0.05 
Methanol 09.81 ± 0.10 
Ethanol 07.83 ± 0.02 
 
To reduce the effects of interfacial energy changes, organic solvents were replaced by 
mixtures of organic solvent and water. Different proportions of water were tested with four organic 
solvents: DMSO, DMF, methanol and ethanol. For each proportion, the interfacial energy with FC-70 
oil was measured, and droplet stability in the tubing was monitored (Figure 11). For all tested organic 
solvents, the addition of water improved the stability of the generated droplets. However, the 
proportion of water required for this stabilization varied from one organic solvent to another: for 
DMSO and DMF, only 10% water is required for droplet stabilization, as compared to 30% for 
methanol and 50% for ethanol. However, for all solvents, the value of the interfacial energy above 
which the droplets are stable in the tubing is in the range 15-20mJ.m-2 (Figure 11). This interfacial 
energy represents a limit below which the droplets are not stable in the tubing, and is very close to 
the critical surface energy of Teflon, 18mJ.m-2.29 The critical surface energy of a solid surface gives 
the maximum interfacial energy of a liquid that wets the surface. Since the FEP surface of the tubing 
resembles that of Teflon, this confirms that the droplets become unstable and tend to coalesce when 
they wet the FEP tubing wall. Consequently, in this FEP microfluidic set-up, the dispersed phase 
(composing the droplets) must have an interfacial energy with the continuous phase higher than 15-
20mJ.m-2 to prevent droplets from coalescing.  
Note that the mixtures of organic solvent and water still solubilize ligands, given that the 
concentrations required are low ( a few mM). Moreover, proteins are not soluble in organic solvent. 
So as not to disturb their three-dimensional structure and compromise crystal quality, the final 
droplets must not contain more than 10% organic solvent.30 Thus, adding water to the ligand 
solutions also reduces the final amount of solvent in the crystallization droplets, decreasing the risk 
of protein denaturation.  
 
Figure 11: Interfacial energy of mixtures (organic solvent/water) with FC-70 oil, as a function of the 
percentage of water in the organic solvents: ethanol (circles), methanol (triangles), DMF (squares) 
and DMSO (diamonds). The empty symbols correspond to the conditions under which the droplets 
coalesce quickly in the tubing, and the full symbols to the conditions under which the generated 
droplets are stable in the tubing. 
This set-up was applied to QR2 crystallization, adding first a 40% DMSO solution, so that the 
final droplets contain 8% DMSO. The crystals grown in these conditions (Figure 12) were similar to 
those obtained in pure aqueous solution (Figure 2), confirming that this DMSO concentration was 
low enough to preserve the protein structure and its crystallization. Then melatonin, a known QR2 
ligand 20, was added to the droplets as a proof of concept for co-crystallization (Figure 13). We 
obtained crystals, which could be confirmed by further XRD analysis as QR2-melatonin co-crystals. 
 
Figure 12: Pictures of 3 representative droplets for QR2 crystallization in presence of 8% DMSO in 
10nL droplets. 6.7mg.mL-1, (NH4)2SO4 1.3M, 150mM NaCl, 20mM Tris-HCl pH 8, DMSO 8%, 20°C.  
 
Figure 13: Pictures of 3 representative droplets for QR2 co-crystallization with melatonin in 10nL 
droplets. QR2 6.7mg.mL-1, (NH4)2SO4 1.5M, 150mM NaCl, 20mM Tris-HCl pH 8, DMSO 7%, 20°C. 
In conclusion, this method is suitable for preliminary screening to discriminate ligands 
favorable to protein crystallization from those which are not. After this selection, the co-
crystallization can be optimized using the fine-gradient method presented here and previously.16 
4. Conclusion 
The droplet-based microfluidic platform described here is a flexible versatile tool for protein 
crystallization. Its three independent modules make it suitable for a wide range of applications: 
screening and optimization of crystallization conditions and screening of co-crystallization 
conditions. Easy to build and to use, the platform can be used to carry out a large number of 
crystallization trials quickly in droplets of only a few nanoliters, with small quantities of materials. 
The droplet composition is controlled by the respective flow-rates of the different solutions, and 
checked by on-line absorbance measurement. Commercially-available microfluidic junctions and 
tubing are combined to afford the number of inlets required and to create the desired geometry for 
droplet generation, without channel design and microfabrication stages. The absence of surfactant 
in droplets avoids any risk of its interaction with the nucleation process or with the protein three-
dimensional structure. Moreover, mixing aqueous and organic phases during droplet generation and 
circulation is rendered possible without using any surfactant.  
Two examples of application to protein crystallization were presented here, using tubing as a 
“chemical library”. First, screening and optimization of crystallization conditions of lysozyme, using 
only 0.2mg of protein for the entire study. Several crystallization agents placed in tubing form a 
“crystallization agent-based chemical library” and are successively added to droplets, making it 
possible to select the most efficient agent. Then crystallization conditions are optimized by varying 
the supersaturation inside the droplets via a fine concentration gradient. Thus, large single protein 
crystals are achieved. Second, the microfluidic geometry for a “ligand-based chemical library” is 
explored to co-crystallize the protein QR2 with ligand, for the purposes of structure-based drug 
design. Therefore, mixing the aqueous phase containing the protein and the crystallization agent 
with the organic phase containing the ligand is possible during droplet generation and circulation. 
The co-crystallization of QR2 protein dissolved in water with melatonin dissolved in DMSO validates 
the microfluidic geometry.  The obtained protein-ligand co-crystals could be further analyzed by XRD 
in-situ (in glass tubing) or ex-situ (by extracting crystals from the Teflon tubing)19, or to solve the 3D 
structure, either to observe the ligand in the protein structure. 
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